Volume 3.25 | Jul 3

Pulmonary Cell News 3.25 July 3, 2014
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
 
TOP STORY
Neurotrophin Receptor TrkB Promotes Lung Adenocarcinoma Metastasis
An in vitro system designed to discover factors critical for lung cancer cell migration identified brain-derived neurotrophic factor, which stimulates cell migration through activation of tropomyosin-related kinase B (TrkB). Knockdown of TrkB in human lung cancer cell lines significantly decreased their migratory and metastatic ability in vitro and in vivo. [Proc Natl Acad Sci USA] Abstract
Request Sample: ReLeSR٬ Easy Passaging Through Selective Detachment of hPSCs
 
PUBLICATIONS (Ranked by impact factor of the journal)
Amphiphilic Polymer-Coated CdSe/ZnS Quantum Dots Induce Pro-Inflammatory Cytokine Expression in Mouse Lung Epithelial Cells and Macrophages
Researchers assessed the effects of tri-n-octylphosphine oxide, poly(maleic anhydride-alt-1-tetradecene) coated CdSe/ZnS quantum dots on mouse lung epithelial cells and macrophages. [Nanotoxicology] Abstract

Bronchial Epithelial Cells Induce Alternatively Activated Dendritic Cells Dependent on Glucocorticoid Receptor Signaling
Scientists recently demonstrated that tracheal epithelial cells continuously secrete soluble mediators that affect the reactivity of local innate immune cells. Using transcriptional profiling, they now observe that conditioning of dendritic cells by tracheal epithelial cells regulated 98 genes under homeostatic conditions. [J Immunol] Abstract

S. pneumoniae ClpL Modulates Adherence to A549 Human Lung Cells through Rap1/Rac1 Activation
Investigators show that caseinolytic protease L (ClpL) impairs pneumococcal adherence to A549 lung cells by inducing and activating Rap1 and Rac1, thus increasing phosphorylation of cofilin (inactive form). [Infect Immun] Abstract

The Moraxella catarrhalis-Induced Pro-Inflammatory Immune Response Is Enhanced by the Activation of the Epidermal Growth Factor Receptor in Human Pulmonary Epithelial Cells
The effects of inhibition and gene silencing of epidermal growth factor receptor on M. catarrhalis-dependent pro-inflammatory cytokine expression in human primary bronchial epithelial cells, as well as the pulmonary epithelial cell lines BEAS-2B and A549 were analyzed. [Biochem Biophys Res Commun] Full Article

LUNG CANCER

EZH2-Mediated Epigenetic Suppression of Long Noncoding RNA SPRY4-IT1 Promotes NSCLC Cell Proliferation and Metastasis by Affecting the Epithelial-Mesenchymal Transition
Researchers show that epigenetic silencing of long noncoding RNA SPRY4 intronic transcript 1 (SPRY4-IT1) occurs in non-small-cell lung cancer (NSCLC) cells through direct transcriptional repression mediated by the Polycomb group protein enhancer of zeste homolog 2 (EZH2). [Cell Death Dis] Full Article

MicroRNA-34a Overcomes HGF-Mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET
Researchers found that the forced expression of miR-34a inhibited cell growth and induced apoptosis partly by targeting MET in hepatocyte growth factor (HGF)-induced gefitinib-resistant HCC827 and PC-9 cells. [Cancer Lett] Abstract

Trim28 Contributes to EMT via Regulation of E-Cadherin and N-Cadherin in Lung Cancer Cell Lines
Scientists found that tripartite motif containing 28 (Trim28) plays a role in TGF-β-induced epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer cells. Silencing Trim28 with inhibitory RNAs alters the expression of numerous EMT markers, such as E-cadherin and N-cadherin, whereas overexpression of Trim28 has an opposite effect. [PLoS One] Full Article

Overexpression of HP1γ Is Associated with Poor Prognosis in Non-Small Cell Lung Cancer Cell through Promoting Cell Survival
Researchers found knockdown of heterochromatin protein 1γ (HP1γ) in A549 and NCI-H1975 cells induced apoptosis accompanied with suppressed cell proliferation and colony formation. [Tumor Biol] Abstract

Read White Paper:  Increase Success Rate Of Compounds In Toxicity Testing
 
REVIEWS
Acquired Resistance to TKIs in Solid Tumors: Learning from Lung Cancer
The authors explore breakthroughs in the understanding and treatment of acquired resistance in non-small-cell lung cancer, focusing on EGFR mutant and ALK rearrangement-positive disease, which may be relevant across multiple different solid malignancies with oncogene-addicted subtypes. [Nat Rev Clin Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
 
INDUSTRY NEWS
COPD: Boehringer Ingelheim Submits Applications in Europe for Tiotropium + Olodaterol Respimat® Fixed-Dose Combination in COPD
Boehringer Ingelheim announced submission of marketing authorization applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol in the Respimat® Soft Mist™ Inhaler as a maintenance bronchodilator treatment for patients with chronic obstructive pulmonary disease (COPD). [Boehringer Ingelheim GmbH] Press Release

PTC Therapeutics Initiates Confirmatory Phase III Clinical Trial of Translarna™ (Ataluren) in Patients with Nonsense Mutation Cystic Fibrosis (nmCF)
PTC Therapeutics, Inc. announced the initiation of a global confirmatory Phase III clinical trial of Translarna™ (ataluren), an investigational new drug, in patients with nmCF. [PTC Therapeutics, Inc.] Press Release

U.S. FDA Accepts NDA Filing for Boehringer Ingelheim’s Investigational Nintedanib and Grants Priority Review Designation for the Treatment of Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim Pharmaceuticals, Inc. announced that the new drug application (NDA) for its investigational compound nintedanib has been accepted for filing by the U.S. Food & Drug Administration (FDA) and granted priority review designation. [Boehringer Ingelheim GmbH] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells?
Watch a video to see how ALDEFLUOR™ can help.
 
POLICY NEWS
Lung Cancer Alliance Commends National Cancer Institute for Its New Scientific Framework for Small Cell Lung Cancer
Today the National Cancer Institute, led by Harold Varmus, MD, presented to Congress a scientific framework that lays out important steps needed to make advances in small cell lung cancer, one of the most lethal forms of the disease. [Lung Cancer Alliance] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW EMBO | EMBL Symposium – Epithelia: The Building Blocks of Multicellularity
August 27-30, 2014
Heidelberg, Germany

Visit our events page to see a complete list of events in the pulmonary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Lung and Vascular Disease (University of Illinois)

Postdoctoral Research Associate – Lung Development Research (Women and Infants Hospital of Rhode Island)

Postdoctoral Research Trainee – Lung Injury and Epithelial Repair (University of Tennessee Health Science Center)

Director, US Medical Affairs – Lung Job (Celgene Corporation)

Postdoctoral Scholar – Molecular Mechanisms of Lung Cancer, Lung Regeneration and Lung Development (University of California – San Francisco)

Primary Cell Culture Position – Heart/Lung Disease (Paramount Recruitment)

Postdoctoral Position – Molecular and Cell Biology (Cornell University)

Junior Research Group Leader Position – Cell-Derived Therapeutics in Chronic Lung Disease (Helmholtz Zentrum München)

Postdoctoral Fellow – Lung Biology and Genomics (Harvard University)

Research Fellow – Pulmonary Cancer (Mayo Clinic – Rochester)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pulmonary Cell News: Archives | Events | Contact Us